LYTENAVA

This brand name is authorized in Austria, Lithuania, UK.

Active ingredients

The drug LYTENAVA contains one active pharmaceutical ingredient (API):

1	Bevacizumab UNII 2S9ZZM9Q9V - BEVACIZUMAB
	Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.
	Read more about Bevacizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LYTENAVA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01LA08		S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1099904